-
Mashup Score: 2FDA's ODAC Supports Proposed Trial for Dostarlimab in dMMR/MSI-H Locally-Advanced Rectal Cancer - 1 year(s) ago
In an 8 to 5 vote, the FDA’s Oncologic Drugs Advisory Committee supported the proposed clinical trial for dostarlimab as treatment of locally advanced, treatment-naïve mismatch-repair deficient or microsatellite-instability-high rectal cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Treatment with dostarlimab (Jemperli) plus chemotherapy reduced the risk of disease progression or death by 30% compared with pembrolizumab (Keytruda) plus chemotherapy as a frontline treatment for patients with metastatic non-squamous non–small cell lung cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Treatment w/ #dostarlimab (#Jemperli) + chemo reduced the risk of disease progression or death by 30% compared with #pembrolizumab (#Keytruda) plus chemotherapy as a frontline treatment for patients with metastatic non-squamous NSCLC. @peters_solange #lcsm https://t.co/8Fi9DRqyNN
-
-
Mashup Score: 0Dostarlimab Plus Chemo Improves Responses in Patients With Advanced Non-Squamous NSCLC - 2 year(s) ago
Findings from the PERLA trial examining the combination of dostarlimab with pemetrexed followed by cisplatin or carboplatin will be presented at an upcoming medical conference. GSK hints that the combination improves objective response compared with pembrolizumab and chemotherapy.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Treatment with #dostarlimab/chemotherapy in patients with first-line metastatic non-squamous #NSCLC achieved a higher ORR compared with #pembrolizumab and #chemotherapy, meeting the primary end point of the phase 2 PERLA trial. #lcsm | @GSK https://t.co/LezqAwFWaO
-
-
Mashup Score: 2Head-to-head trial of dostarlimab vs. pembrolizumab in lung cancer achieves key endpoint - 2 year(s) ago
A head-to-head trial of the PD-1 inhibitors dostarlimab and pembrolizumab, each in combination with chemotherapy, met its primary endpoint of objective response rate among patients with metastatic nonsquamous non-small cell lung cancer.Topline data from the randomized, phase 2 PERLA trial also showed dostarlimab (Jemperli, GSK) had a safety profile consistent with similar regimens in previous
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Dostarlimab VS. #Pembrolizumab: Head-to-head trial achieves key endpoint. https://t.co/UVoBpidAe4 #lungcancer #Jemperli @GSKUS #Keytruda @Merck #OncAlert #HemOnc #drugtrials #cancerresearch #Oncology
-
-
Mashup Score: 0Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Pharmacy Forum: #Dostarlimab is an anti-PD-1 humanized IgG4 monoclonal antibody. It inhibits programmed cell death 1 (PD-1) activity through binding to the PD-1 receptor located on T cells to block PD-L1 and PD-L2 ligands from binding: https://t.co/J2pqN9HMk2 #pharmaonc https://t.co/62IKu1nPea
-
-
Mashup Score: 0Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Pharmacy Forum: #Dostarlimab is an anti-PD-1 humanized IgG4 monoclonal antibody. It inhibits programmed cell death 1 (PD-1) activity through binding to the PD-1 receptor located on T cells to block PD-L1 and PD-L2 ligands from binding: https://t.co/J2pqN9HMk2 #pharmaonc https://t.co/q9EJTT5KvF
-
-
Mashup Score: 2
In an interview with Targeted Oncology, Gerald Falchook, MD, discusses the efficacy and safety of cobolimab with or without nivolumab and dostarlimab, as evaluated in the phase 1 AMBER trial.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In an interview with Targeted Oncology, Gerald Falchook, MD, discusses the efficacy and safety of #cobolimab with or without #nivolumab and #dostarlimab, as evaluated in the phase 1 AMBER trial. #melsm #skcsm https://t.co/OVoq109tIE
-
-
Mashup Score: 7
Original Article from The New England Journal of Medicine — PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
Source: New England Journal of MedicineCategories: Latest Headlines, Oncologists2Tweet-
A new immune checkpoint inhibitor for treating cancer? #dostarlimab, an anti–PD-1 monoclonal reported @NEJM https://t.co/QjvCbvPZze @NYTimes headline: A Cancer Trial’s Unexpected Result: Remission in Every Patient, @ginakolata https://t.co/JBtkHXgeBR? #crcsm
-
-
Mashup Score: 0
FDA grants accelerated approval for GSK’s JEMPERLI (dostarlimab-gxly) for women with recurrent or advanced dMMR endometrial cancer
Source: Oncology CentralCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Discover more about the approval of #Dostarlimab in #EndometrialCancer and the GARNET trial in our latest news:https://t.co/Pslh3RGVfB
-
-
Mashup Score: 0
FDA grants accelerated approval for GSK’s JEMPERLI (dostarlimab-gxly) for women with recurrent or advanced dMMR endometrial cancer
Source: Oncology CentralCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Register for free to @OncologyCentral now to gain free access to @FutureOncol_FSG's Drug Evaluation on #Dostarlimab in #EndometrialCancer https://t.co/E9MA20q8qQ
-
The FDA's #ODAC voted 8 to 5 in favor of the development of #dostarlimab for the treatment of human patients with locally advanced, treatment-naïve dMMR or MSI-H rectal cancer. #crcsm #FDA https://t.co/7rYfG8r02r